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Introduction
Preeclampsia is a multisystem complex disease of pregnancy with 
grave maternal-fetal and neonatal consequences that complicates 
up to 8% of pregnancies (1, 2). Low vitamin D status, among other 
risk factors, is linked to the development of preeclampsia. System-
atic reviews and meta-analyses have concluded that low serum 
BACKGROUND. Low vitamin D status in pregnancy was proposed as a risk factor of preeclampsia. 
METHODS. We assessed the effect of vitamin D supplementation (4,400 vs. 400 IU/day), initiated early in pregnancy (10–18 
weeks), on the development of preeclampsia. The effects of serum vitamin D (25-hydroxyvitamin D [25OHD]) levels on 
preeclampsia incidence at trial entry and in the third trimester (32–38 weeks) were studied. We also conducted a nested case-
control study of 157 women to investigate peripheral blood vitamin D–associated gene expression profiles at 10 to 18 weeks in 
47 participants who developed preeclampsia.
RESULTS. Of 881 women randomized, outcome data were available for 816, with 67 (8.2%) developing preeclampsia. There was 
no significant difference between treatment (N = 408) or control (N = 408) groups in the incidence of preeclampsia (8.08% vs. 
8.33%, respectively; relative risk: 0.97; 95% CI, 0.61–1.53). However, in a cohort analysis and after adjustment for confounders, 
a significant effect of sufficient vitamin D status (25OHD ≥30 ng/ml) was observed in both early and late pregnancy compared 
with insufficient levels (25OHD <30 ng/ml) (adjusted odds ratio, 0.28; 95% CI, 0.10–0.96). Differential expression of 348 
vitamin D–associated genes (158 upregulated) was found in peripheral blood of women who developed preeclampsia (FDR 
<0.05 in the Vitamin D Antenatal Asthma Reduction Trial [VDAART]; P < 0.05 in a replication cohort). Functional enrichment 
and network analyses of this vitamin D–associated gene set suggests several highly functional modules related to systematic 
inflammatory and immune responses, including some nodes with a high degree of connectivity.
CONCLUSIONS. Vitamin D supplementation initiated in weeks 10–18 of pregnancy did not reduce preeclampsia incidence in 
the intention-to-treat paradigm. However, vitamin D levels of 30 ng/ml or higher at trial entry and in late pregnancy were 
associated with a lower risk of preeclampsia. Differentially expressed vitamin D–associated transcriptomes implicated the 
emergence of an early pregnancy, distinctive immune response in women who went on to develop preeclampsia.
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in the vitamin D treatment group as compared with that in the pla-
cebo group. However, women who had sufficient vitamin D levels 
(at least 30 ng/ml) in both early and late pregnancy, regardless of 
treatment group, showed a significantly lower incidence of pre-
eclampsia as compared with those who had an insufficient level at 
these time points (2.25% vs. 11.92%; RR, 0.20; CI, 0.06–0.66; P < 
0.008). Within the treatment and placebo control groups, trends 
toward a decreased occurrence of preeclampsia were observed 
among women who had sufficient vitamin D status (≥30 ng/ml) in 
both early and late pregnancy (high-high 25OHD: odds ratio [OR], 
0.6; CI, 0.35–1.06; P = 0.08 and OR, 0.35; CI, 0.16–0.78; P = 0.01, 
respectively). The pooled estimate of the OR in the intention-to-
treat (ITT) population was 0.55 (CI, 0.37–0.82; P < 0.003). After 
covariate adjustment (Table 2), women with sufficient vitamin D 
concentrations at both 10 to 18 and 32 to 38 weeks of gestation had 
a substantially reduced risk of preeclampsia (adjusted OR, 0.28; 
CI, 0.08–0.96; P = 0.04). 25OHD serum concentrations in early 
pregnancy were a predictor of preeclampsia (adjusted OR, 0.96; 
CI, 0.93–0.99; P  =0.025), such that a 10-, 20-, or 30-unit increase 
(ng/ml) was associated with a 33%, 54%, and 70% reduction in 
the risk of preeclampsia, respectively (adjusted OR10-unit = 0.67; 
95% CI, 0.47–0.95; adjusted OR20-unit = 0.46; 95% CI, 0.22–0.90; 
adjusted OR30-unit = 0.30; 95% CI, 0.16–0.85, respectively). No 
occurrence of preeclampsia was noted in women with a baseline 
serum value above 37 ng/ml. Accordingly, the adjusted estimat-
ed probability of preeclampsia was less than 0.05 at an approxi-
mate vitamin D serum level of 40 ng/ml (100 nmol/l) during early 
pregnancy (Figure 2).
Early pregnancy vitamin D status modulates the expression of 
preeclampsia transcriptome signatures. Marginal comparisons of 
distributions of maternal age, race, and gestational age at enroll-
ment in the VDAART discovery or replication cohort were consis-
tent with the effectiveness of the matching procedures used (all 
P > 0.05, minimum P = 0.12; Table 3). 25OHD serum levels were 
significantly lower in women in the VDAART discovery cohort 
who developed preeclampsia (P = 0.004). Overall, in the discov-
ery cohort, 119 subjects had insufficient vitamin D status (<30 ng/
ml, 41 with preeclampsia), and 38 subjects had sufficient vitamin 
D status (≥30 ng/ml, 6 positive for preeclampsia), respectively 
(Figure 3). In the VDAART cohort, 2,829 genes were identified as 
differentially expressed among women with 25OHD levels dichot-
omized at 30 ng/ml (1,081 upregulated). The pregnant women 
who developed preeclampsia had 1,547 genes (611 upregulated) 
that were differentially expressed relative to those of controls. 
The intersection of the vitamin D gene signatures and the pre-
eclampsia gene signatures represented vitamin D gene signatures 
associated with preeclampsia, i.e., 1,323 unique genes (592 upreg-
ulated). Of these genes, 348 (158 upregulated) were differential-
ly expressed in peripheral blood in preeclamptic subjects versus 
controls in the OMEGA study (marginal per gene, P < 0.05, Fig-
ure 3 and Supplemental Table 1; supplemental material available 
online with this article; doi:10.1172/JCI89031DS1). From the total 
348 replicated differentially expressed genes, 33 genes were iden-
tified in a database search, and manual curation of the literature 
revealed an additional 107 genes with a prior known association 
with preeclampsia (140 of 348, 40.23%; Supplemental Table 2). 
The replicated gene signatures also showed tissue-specific enrich-
vitamin D levels (25-hydroxyvitamin D [25OHD]) in pregnancy 
are associated with a higher risk of preeclampsia and suggest a 
preventive role of vitamin D supplementation (3–6). However, a 
recent meta-analysis of the 3 vitamin D supplementation random-
ized clinical trials (RCTs) on pregnancy outcomes found no asso-
ciation between increased serum vitamin D levels and preeclamp-
sia risk (7). Although these studies vary in the dose of vitamin D 
supplementation (400–4,000 IU/day) and in the baseline and 
attained vitamin D levels, it is most important to note that all of 
the RCTs started the intervention after 20 weeks of gestation. It 
is noted that this meta-analysis did not include the results of the 
National Institute of Child Health and Development (NICHD) 
trial that started vitamin D supplementation before 20 weeks of 
gestation (8). A meta-analysis of the abnormal maternal biomark-
ers found during the first trimester of pregnancy in women who 
developed preeclampsia and the findings of previous studies on 
the association of preeclampsia and low vitamin D status in ear-
ly pregnancy suggest the necessity of early serum vitamin D level 
surveillance and modification in pregnancy (5, 9). As such, our tri-
al, the Vitamin D Antenatal Asthma Reduction Trial (VDAART), 
investigated the effect of early pregnancy vitamin D supplemen-
tation and both early and late pregnancy 25OHD levels on the risk 
of preeclampsia, one of the a priori–defined outcomes of the trial.
Previous investigations have also shown the effect of vitamin 
D levels on peripheral blood gene expression during pregnancy 
and in preeclampsia (10, 11). Global gene expression profiling has 
the potential to identify representative pathway genes that might 
point to the underlying molecular mechanism of preeclampsia 
(12–15). Therefore, we performed a nested case-control study in 
the VDAART to identify vitamin D gene signatures related to pre-
eclampsia during early pregnancy. There is increasing evidence 
that disease signature and causal genes do not distribute random-
ly on the molecular interaction network (interactome), but rather 
interact in similar biological pathways (16, 17). Accordingly, we 
applied a molecular interaction network approach using informa-
tion from differential expression and a protein-protein interaction 
network to identify interacting key drivers (preeclampsia module) 
of the vitamin D gene signatures.
Results
Low vitamin D status in early pregnancy and throughout is associ-
ated with a higher risk of preeclampsia. Of 9,268 women who were 
screened, 881 were randomized. After exclusion of 5 ineligi-
ble women, 440 were assigned to receive vitamin D and 436 to 
receive placebo (Figure 1). A total of 32 women in the treatment 
group and 28 in the placebo group (60 of 876, 6.8% overall) were 
lost to follow-up.
Among the baseline characteristics, gravidity was significant-
ly different between the 2 study groups (Table 1). Vitamin D levels 
during the third trimester in the treatment group amounted to 39 
± 15 ng/ml versus 27 ± 11 ng/ml in the placebo group (P < 0.0001). 
No side effects or adverse events were reported in association with 
vitamin D supplementation. Preeclampsia occurred in 33 women 
in the treatment group (8.08%) as compared with 34 women in the 
placebo group (8.33%) (relative risk [RR], 0.97; 95% CI, 0.61–1.53). 
While vitamin D supplementation increased 25OHD levels in the 
third trimester, no reduction in the rate of preeclampsia was seen 
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(86.78%) replicated differentially expressed genes were mapped 
onto the interactome and demonstrated local clustering in the net-
work (preeclampsia module vs. random expectation, P <0.0001; 
Figure 5). We identified the “observable preeclampsia module” 
consisting of 143 genes with 552 connections, among them IL8 
(also known as CXCL8), MX1, HLA-DP1A, HLA-DBQB1, MMP9, 
RPL31, ACTA2, IFI44L, and SERPING1, all of which were pre-
viously reported to be in association with preeclampsia (Supple-
ment in placenta (P < 0.0001); according to the Human Protein 
Atlas, 181 genes had evidence of an expression value in placenta 
(placenta signatures: 181 of 348 [52.01%], 68 in decidua [19.54%], 
15 in trophoblast [4.31%], and 98 [28.16] in both; Figure 4 and Sup-
plemental Table 3).
Interactome mapping demonstrates interacting immunomud-
ulatory gene signatures in early pregnancy in women who develop 
preeclampsia. Three hundred two of three hundred forty-eight 
Figure 1. VDAART preeclampsia CONSORT diagram.
Downloaded from http://www.jci.org on January  4, 2017.   https://doi.org/10.1172/JCI89031
The Journal of Clinical Investigation   C L I N I C A L  M E D I C I N E
4 7 0 5jci.org   Volume 126   Number 12   December 2016
corrected P < 0.05; Supplemental 
Table 4). Similarly, the observ-
able preeclampsia module was 
associated with immune system 
process, response, and regulation 
(N = 57, 45, and 27, respectively; 
all corrected P < 0.05; Supple-
mental Table 5).
Discussion
In the VDAART, supplemen-
tation with vitamin D initiated 
between 10 and 18 weeks of 
gestation did not reduce the fre-
quency of preeclampsia in the 
ITT analysis. However, women 
who had sufficient vitamin D 
levels (≥30 ng/ml) at enrollment 
in early pregnancy and retained 
that status in late pregnancy had 
a significantly lower rate of pre-
eclampsia compared with wom-
en with insufficient vitamin D 
levels (P = 0.04). This finding, 
along with the biological signifi-
cance of the identified peripheral 
blood gene expression signatures 
in women who developed pre-
eclampsia, implicates early preg-
nancy vitamin D status in the 
development of the disease.
Despite evidence from 
observational studies showing 
an association of low vitamin 
D status during pregnancy with 
preeclampsia (3–6), few random-
ized trials have examined the 
effectiveness of vitamin D sup-
plementation in pregnancy out-
comes, particularly in prevent-
ing preeclampsia (5, 7, 8, 18, 19). 
These trials had a smaller sample 
size, and in only 1 study was the 
therapy initiated approximately 
as early as it was in the VDAART 
(8). Except for the 1 other trial started early in pregnancy (8) and 
a recent trial of vitamin D supplementation after 20 weeks of 
gestation (19), the doses of vitamin D used were less than those 
in VDAART. No other trial, to our knowledge, has explored the 
underlying biological mechanisms using expression profiling and 
functional annotation of identified genes.
The inverse association between maternal vitamin D con-
centrations in early pregnancy and risk of preeclampsia in the 
VDAART is consistent with the findings of previous observation-
al studies (20–22). A noteworthy finding of the VDAART is that 
a circulating vitamin D level of approximately 40 ng/ml during 
pregnancy seems to minimize the vitamin D–associated risk of 
mental Table 2) and showed the highest degree of connectivity 
in the interactome. This module was significantly close to known 
signaling pathways for both IL-10 and vitamin D (Z scores –8.6 
and –3.8, respectively, P ≤ 0.0001; Figure 6 and Table 4). Gene 
ontology (GO) enrichment analysis linked the 348 replicated gene 
signatures to several immunologic functions including immune 
system process, response, and regulation (N = 109, 83, and 63, 
respectively); innate and adaptive immune response (N = 50 and 
19, respectively); inflammatory response (N = 35); IL-10 produc-
tion and negative regulation (N = 8 and 7, respectively); regulation 
of cytokine production (N = 25); and type I IFN–signaling pathway 
and cellular response to type I IFN (N = 10 and 10, respectively, all 
Table 1. Baseline maternal characteristics in the VDAART
4,400 IU (n = 408) 400 IU (n = 408) P value
Clinical center
 San Diego, n (%) 136 (33) 141 (35) 0.68
 Boston, n (%) 118 (29) 125 (31)
 St. Louis, n (%) 154 (38) 142 (35)
Age in years, mean (SD) 27.5 (5.4) 27.2 (5.6) 0.34
 <30, n (%) 258 (63) 268 (66) 0.64
 30–34, n (%) 121 (30) 109 (27)
 ≥35, n (%) 29 (7) 31 (8)
Gravidity, including in the VDAART, mean (SD) 2.6 (1.7) 2.3 (1.4) 0.008
Gestational age in weeks at enrollment, mean (SD) 14.2 (2.8) 14.2 (2.7) 0.86
Gestational age in weeks at delivery, mean (SD) 38.7 (2.13) 38.8 (2.42) 0.83
BMI at first appointment, mean (SD) 28.9 (7.7) n = 382 29.0 (7.6) n = 391 0.77
Baseline vitamin D (25OHD) in ng/ml, mean (SD) 23.32 (10.3) n = 405 22.6 (10.2) n = 406 0.29
Third trimester 25OHD in ng/ml, mean (SD) 39.2 (15.34) n = 386 26.8 (10.74) n = 391 <0.0001
Third trimester 25OHD ≥30 ng/ml, n (%) 290 (74.2) 135 (35) <0.0001
Mother
 Asthma, n (%) 173 (42) 154 (38) 0.17
 Allergic rhinitis, n (%) 258 (63) 264 (65) 0.66
 Eczema, n (%) 128 (31) 132 (32) 0.76
Race/ethnicity
 Black/African-American, n (%) 178 (44) 177 (43) 0.99
 White/Hispanic, n (%) 55 (13) 58 (14)
 White/non-Hispanic, n (%) 108 (26) 108 (26)
 Other, n (%) 67 (16) 65 (16)
Education level completed
 Lower than high school, n (%) 63 (15) 39 (10) 0.052
 High school, technical school, n (%) 111 (27) 133 (33)
 Some college, n (%) 98 (24) 96 (24)
 College graduate/graduate school, n (%) 136 (33) 140 (34)
Marital status
 Married, n (%) 179 (44) 193 (47) 0.59
 Divorced/separated, n (%) 12 (3) 10 (2)
 Not married, n (%) 217 (53) 205 (50)
Household income (US $)
 <$30,000, n (%) 122 (30) 117 (29)
 $30,000–49,999, n (%) 50 (12) 55 (13)
 $50,000–74,999, n (%) 48 (12) 50 (12)
 $75,000–99,999, n (%) 42 (10) 37 (9)
 $100,000–149,000, n (%) 33 (8) 31 (8)
 >$150,000, n (%) 18 (4) 13 (3)
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vitamin D3 supplementation (24). 
These observations suggest that 
the current criterion for vitamin 
D deficiency (<20 ng/ml) of the 
Institute of Medicine (IOM) may 
be a suboptimal vitamin D lev-
el for pregnancy-related adverse 
events such as preeclampsia. Our 
observation is also consistent with 
the contemporary understanding 
of preeclampsia as arising from a 
preclinical phase of aberrant pla-
centation in early pregnancy (25). 
These data suggest that earlier 
supplementation with vitamin D, 
even prior to implantation of the 
embryo, may be needed to improve 
vitamin D status in pregnant wom-
en to prevent preeclampsia, a 
notion that should be examined in 
a clinical trial.
Our gene expression substudy 
identified a set of vitamin D–asso-
ciated genes related to preeclamp-
sia, and network-based closeness 
demonstrated their connectivity 
to known vitamin D–signaling 
pathways, indicating the function-
al cohesiveness of vitamin D to 
the preeclampsia disease module. 
Most of the genes in the replicat-
ed module were associated with 
maternal systemic changes in 
immune (innate and humoral) and 
inflammatory responses. Among 
the functional interactions, one of 
the identified biological processes 
is negative regulation and produc-
tion of IL-10 expression. IL-10 is 
an antiinflammatory cytokine that 
also mediates innate and humor-
al immune responses. Decreased 
IL-10 levels in placenta and in serum of women with preeclampsia 
have been observed (26, 27). 1,25(OH)2D3 decreases the synthesis 
of IL-12 and IL-23 and increases the production of IL-10 by DCs 
(28). This effect results in a decrease in Th1 cell responses, pro-
ducing more Tregs and a Th2 profile that favors a state of immune 
tolerance to the fetus in the mother (29). IL-10 has also been 
implicated in placental angiogenesis, growth, and remodeling and 
in blunting hypoxic injury at the maternal-fetal interface (29, 30). 
Additionally, the identified preeclampsia module of replicated 
genes was significantly close and connected to the known IL-10 
pathways in the interactome (P ≤ 0.0001).
Why was therapy with vitamin D not successful in modifying 
the incidence of preeclampsia in the VDAART or in previous stud-
ies? It is possible that vitamin D supplementation and the subse-
quently increased maternal vitamin D metabolites are not import-
preeclampsia. Our data are consistent with the NICHD trial’s con-
clusion that a level of 40 ng/ml of circulating 25OHD is required 
to support maximum 1,25(OH)2D production during pregnancy (8, 
23). In the NICHD trial, 4,000 IU versus 2,000 and 400 IU vita-
min D were given after 12 to 16 weeks of gestation, with 4,000 IU 
having the greatest effect on reducing the composite rate of preg-
nancy comorbidities. Furthermore, across the  treatment arms of 
this trial (400, 2,000, and 4,000 IU vitamin D), there was a trend 
toward a significant effect on the odds of pregnancy hypertensive 
disorder including preeclampsia after controlling for race (P = 
0.05) (8). The observed effect is consistent with the findings of a 
recent trial of vitamin D supplementation (60,000–480,000 IU 
dose determined by a baseline 25OHD of >20, 10–20, and <10 
ng/ml; 49% <10 ng/ml) after 20 weeks of gestation (19). As with 
the NICHD trial, we did not observe any adverse events due to 
Table 2. Logistic regression; effects of treatment arm and vitamin D levels on preeclampsia
Terms Univariate  
OR (95% CI)
Multivariable (all covariates) 
OR (95% CI)
Stepwise regression  
adjusted OR (95% CI)
Treatment arm
 Active 1 1 –
 Placebo 1.03 (0.62–1.70) 0.7 (0.4–1.29) –
First and third trimester vitamin D
 Low-low 1 1 1
 Low-high or high-low 0.62 (0.37–1.04) 0.68 (0.37–1.28) 0.79 (0.45–1.38)
 High-high 0.19 (0.06–0.6) 0.25 (0.07–0.87) 0.28 (0.08–0.96)A
Maternal age (yr)
 <35 1 1 –
 ≥35 0.78 (0.27–2.24) 0.96 (0.27–3.3) –
Maternal BMI at first appointment 
(kg/m2)
1.05 (1.02–1.08) 1.04 (1.002–1.07) 1.04 (1.01–1.07)B
Maternal marital status
 Not married/divorced 1 1 –
 Married 0.52 (0.3–0.88) 0.7 (0.33–1.60)
Annual family income
 <$50,000 1 1 –
 ≥$50,000 0.75 (0.4–1.4) 1.4 (0.77–2.5) –
 Unknown or refused to report 1.4 (0.6–3.4) 1.36 (0.7–2.6) –
Gravidity
 Multigravid 1 1 1
 Nulligravid 1.37 (0.82–2.27) 1.7 (0.9–3.0) 1.70 (1.003–3.03)
Clinical centers
 Site 1 1 1 1
 Site 2 1.01 (0.49–2.06) 0.60 (0.22–1.5) 0.69 (0.32–1.49)
 Site 3 2.05 (1.12–3.7) 0.99 (0.39–2.5) 1.52 (0.79–2.92)
Race/ethnicity
 White/mixed European descent 1 1 –
 Black/African-American 1.65 (0.94–2.9) 1.07 (0.47–2.4) –
 Other 1.2 (0.55–2.6) 0.95 (0.37–2.4) –
Maternal education level
 Lower than college 1 1 1
 College and above 0.36 (0.18–0.7) 0.43 (0.17–1.08) 0.4 (0.21–0.84)C
Categories of 25OHD levels: high-high, subjects who had ≥30 ng/ml at randomization and in the third 
trimester; high-low, subjects who had ≥30 ng/ml at randomization but <30 ng/ml in the third trimester; low-
high, subjects who had <30 ng/ml at randomization but ≥30 ng/ml in the third trimester; low-low, subjects 
who had <30 ng/ml at both time points. AP = 0.04, BP = 0.016, and CP = 0.015.
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ant in the modification of pathophysiologic alterations involved 
in the development of preeclampsia. However, the fact that the 
observed association of maternal vitamin D levels with a risk of 
preeclampsia was reported in several other studies under different 
study conditions (5, 8) leads us to deduce that the observed asso-
ciation in the VDAART results is worthy of further investigation, 
and that conclusion is supported by our gene expression study.
The timing of vitamin D administration and achievement of 
optimal vitamin D concentration are important. Immunologic evi-
dence, detection of early biomarkers, as well as aberrant placental 
development and function suggest that preeclampsia is a disorder 
of early placentation (28, 31–35). Sufficient vitamin D levels need 
to be present at the time of implantation and placentation, the 2 
stages in which maternal-fetal immune interfaces play an import-
ant role in preeclampsia (36, 37). A significant effect of vitamin 
D3 on human extravillous trophoblast invasion in early pregnan-
cy was observed at a concentration of 40 ng/ml (38). Our gene 
expression substudy showed the existence of distinctive biological 
processes consistent with preeclampsia as early as the tenth week 
of pregnancy in women with low vitamin D status who went on 
to develop preeclampsia compared with what was observed in the 
vitamin D–sufficient matched controls. These observations are 
suggestive of the evolution of systematic immunologic alterations 
at the earliest placental stage and prior to the time of enrollment 
in the VDAART. On the contrary, those with vitamin D sufficien-
cy at trial entry (21.8%) and who maintained that status through 
their late pregnancy demonstrated a considerably lower risk of 
preeclampsia. Although vitamin D is implicated in the pathophys-
iology of preeclampsia, it is possible that the role of vitamin D is 
mediated by other interacting factors (environmental or genetic), 
such that a subgroup of pregnant women with low vitamin D status 
might achieve the greatest benefit from this therapy. The observed 
variability in a dose-response association between maternal vita-
min D levels and risk of preeclampsia, particularly at lower con-
centrations, supports this notion (Figure 2). It should also be noted 
that the 4,000 IU dose of vitamin D3 in the VDAART resulted in a 
sufficient level of serum vitamin D (≥30 ng/ml) in only 74% of the 
pregnancies at 32 to 38 weeks of gestation, which is less than the 
82% at 1 month prior to delivery in the NICHD trial on a similar 
dose (23). The results of these 2 studies highlight the latest emerg-
ing evidence that higher supplementation doses (2,000–6,000 
IU/day) than the current recommendation of 400 to 600 IU/day, 
particularly in the absence of adequate sun exposure or other high-
risk conditions of vitamin D deficiency, might be required to sup-
port sufficient levels throughout 
pregnancy. While the current 
evidence from randomized con-
trolled trials (RCTs) is not suffi-
cient to support 25OHD screen-
ing and high-dose vitamin D 
supplementation (>2,000 IU) 
in all pregnant women (39, 40), 
screening and modification of 
vitamin D status in early preg-
nancy and ideally before preg-
nancy for women with a high 
risk of vitamin D deficiency 
should be considered. Further-
more, for to-be pregnant wom-
en with a high risk of vitamin 
D deficiency as well as a risk of 
nonadherence to vitamin D sup-
Figure 2. Dose-response association between mater-
nal serum 25OHD concentrations at 10 to 18 weeks of 
gestation and the corresponding predicted probability of 
preeclampsia derived from a logistic regression model 
adjusted for the identified confounders (Table 2). The gray 
zone indicates 0.95 confidence bands (Npreeclampsia= 67, Nhealthy 
= 749). The minimum predicted risk for the population 
under study relative to the distribution of pregnant women 
(vertical tick marks on the x axis) falls at the concentrations 
of 40 to 50 ng/ml serum vitamin D.
Table 3. Clinical characteristics of the genomic study cohorts
Characteristics Discovery cohort (VDAART) Replication cohort (OMEGA)
Preeclampsia  
(n = 47)




No preeclampsia  
(n = 16)
Gestational age (wk), range 10–18 10–18 11–18 11–18
Age in years, mean (SD) 25.8 (5.0) 26.6 (5.1) 34.7 (4.5) 31.6 (5.5)
Race (n)
 White 17 42 12 13
 Black 22 61 2 1
 Other 8 7 0 2
Serum 25OHD (ng/ml)
 Mean (SD) 19.7 (8.3) 24.4 (14.5) 27.6 (8.6) 27.4 (6.5)
 Missing (n) – – 3 7
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plementation, prepregnancy supplementation strategies such as a 
high dose of vitamin D3 in addition to individualized supplemen-
tation doses should be considered, and frequent 25OHD measure-
ments during pregnancy are recommended (41). These concepts 
need to be definitively tested in a prepregnancy clinical trial in a 
population of women at high risk of preeclampsia.
A limitation of the VDAART as well as other RCTs of vitamin 
D supplementation during pregnancy was that subjects with vita-
min D sufficiency, i.e., those with a level above 30 ng/ml, were not 
screened and were excluded from the trial. While this approach 
might have affected the efficacy of vitamin D supplementation, it 
provided the opportunity to obtain valuable knowledge by allow-
ing us to compare the pregnant women with vitamin D sufficiency 
with  those with vitamin D insufficiency in terms of their risk of 
preeclampsia occurrence and to identify potential mechanisms of 
preeclampsia in early pregnancy. It is noteworthy that a maternal 
or paternal history of allergic diseases has not been recognized as 
a risk factor for preeclampsia; nevertheless, this inclusion criteri-
on for the VDAART might limit the broad generalizability of our 
results in certain populations of pregnant women.
In conclusion, 4,400 IU daily supplementation of vitamin D 
initiated at 10 to 18 weeks of gestation did not show a protective 
effect against preeclampsia in our ITT analysis; however, vitamin 
D sufficiency (≥30 ng/ml) at randomization and at 32 to 38 weeks 
of gestation was associated with a significant (P = 0.04) effect on 
reducing the risk of preeclampsia development. This observation 
and the identified peripheral blood gene expression patterns of 
preeclamptic women showing immune gene activation at 10 to 
18 weeks of gestation highlight the importance of vitamin D suffi-
ciency in early pregnancy.
Methods
VDAART design, participants, interventions, and oversight. The VDAART 
was a randomized, double-blind, placebo-controlled clinical trial of 
vitamin D supplementation (4,000 IU vitamin D plus a multivitamin 
with 400 IU vitamin D daily) versus placebo (placebo pill plus a multi-
vitamin with 400 IU vitamin D daily) for pregnant women with a high 
risk of atopic disease in their family; the goal of the trial was to prevent 
asthma in children as well as predefined pregnancy outcomes, including 
preeclampsia. Participants were 10–18 weeks pregnant and between the 
ages of 18 and 40 years when recruited at obstetric clinics at 3 centers in 
the United States: Boston University Medical Center in Boston, Massa-
chusetts; Washington University in St. Louis, Missouri; and Kaiser Per-
manente Southern California Region in San Diego, California.
Eligible participants were screened between October 2009 and 
July 2011 and enrolled if they met the eligibility criteria. Compliance 
with daily pill taking during pregnancy was monitored via the Medi-
cal Event Monitoring System (MEMS) (www.aardexgroup.com). The 
Data and Safety Monitoring Board (DSMB), convened by the Nation-
al Heart, Lung, and Blood Institute (NHLBI), met every 6 months to 
review recruitment, adherence, adverse events, data quality, and pro-
tocol changes. Details of the trial design and protocol as well as further 
information on the screening, random allocation and blinding pro-
cess, compliance assessment, statistical power, and trial monitoring 
have been published previously (24, 42). The results of the trial were 
prepared and reported in accordance with the Consolidated Standards 
of Reporting Trials (CONSORT) guidelines.
VDAART and eligibility. The VDAART (www.vdaart.com) 
was sponsored by the NHLBI and registered at ClinicalTrials.gov 
(NCT00920621). The VDAART involved pregnant women with sin-
gleton pregnancies at 10 to 18 weeks of gestation, who were enrolled in 
Figure 3. Gene expression study flow chart. 
Summary of analysis approach and findings 
on gene expression analysis, through discovery 
and replication stages. Gene expression study 
was conducted using RankPord to identify 
differentially expressed genes in both discovery 
and replication cohorts (N = 157 and 30, respec-
tively). PE, preeclampsia; DE, differentially 
expressed; VDGS, vitamin D gene signatures; 
PEGS, preeclampsia gene signatures; VDGSPE, 
vitamin D gene signatures associated with 
preeclampsia; rVDGSPE, replicated vitamin D 
gene signatures associated with preeclampsia; 
PPI, protein-protein interaction.
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center’s principal investigator, that would inhibit compliance with the 
study medications or prohibit long-term participation in the trial.
Assessment of compliance: MEMS. The primary measure of compli-
ance with pill taking was monitored via the MEMS (AARDEX Group; 
http://www.aardexgroup.com), which consists of a pill bottle equipped 
with special cap that includes an electronic microchip that stores the 
date and time of each opening of the bottle. Each monitor recorded 
the time and date of each opening and closing of the container through 
integrated microcircuitry. The MEMS stores up to 3,800 medication 
events in nonvolatile, electrically erasable, programmable read-only 
memory (EEPROM), allows wireless data transfer, fits standard phar-
macy bottles, provides 36 months of battery life, and is water resis-
tant and CE marked. Monitors were designed for usage by 1 patient 
with 1 drug. A reader allowed transfer of the dose-timing data from 
the MEMS to a Microsoft Windows–based computer. Data from the 
MEMS were downloaded at the monthly in-person prenatal visits and 
after delivery. The data from the prenatal follow-up visits were used 
to provide feedback to the participant, reinforcing those participants 
with good adherence and providing extra teaching and encourage-
ment for those with suboptimal adherence. The data from both prena-
tal follow-up and postnatal downloads were used to derive a summary 
adherence measure, to be used as a covariate in our analyses. In addi-
tion to the information obtained from the MEMS, the 25OHD levels 
detected from the baseline measurement and at the third-trimester 
visits provided excellent adherence information for this trial.
Data collection on the VDAART subjects. The research staff met 
with the participants monthly, in conjunction with their regularly 
scheduled obstetrical visits. At these visits, a short maternal health 
questionnaire was administered, MEMS cap information was down-
loaded, and study medication and prenatal vitamins were refilled. At 
these monthly prenatal visits, the research staff conducted monthly 
reviews of electronic medical records to check for pregnancy compli-
a multicenter, randomized trial for assessment of the defined outcome 
of pregnancy after receiving either vitamin D (cholecalciferol, 4,000 
IU/day, equivalent to 100 μg/day) or placebo. All pregnant participants 
received prenatal vitamins containing 400 IU (10 μg/day) of cholecal-
ciferol; thus, the vitamin D treatment arm received a total of 4,400 IU/
day (110 μg/day), and the placebo arm received 400 IU/day (10 μg/
day). The pregnant women’s clinical course was followed prospectively 
from randomization (10–18 weeks) to the end of the pregnancy and for 
investigation of predefined pregnancy outcomes including preeclamp-
sia, preterm birth, and term delivery. The inclusion criteria were as 
follows: (a) Maternal history or biological paternal history of asthma, 
eczema, or allergic rhinitis. Pregnant women were considered asthmat-
ic or allergic if they gave a positive answer to the direct question in the 
enrollment questionnaire or any subsequent monthly questionnaire; 
(b) gestational age between 10 and 18 weeks at the time of randomiza-
tion; (c) maternal age between 18 and 39 years; (d) not a current smoker 
(defined as not having smoked for at least 1 month prior to enrollment) 
and not a user of other nicotine products (e.g., nicotine patch) for at 
least 1 month prior to enrollment; (e) English- or Spanish-speaking; (f) 
intention to participate in the trial throughout the pregnancy.
The exclusion criteria were as follows: (a) Gestational age beyond 
18 weeks; (b) presence of any of the following chronic medical condi-
tions: (i) hypertension (on medication); (ii) diabetes mellitus; (iii) para-
thyroid disease; (iv) uncontrolled thyroid disease; (vi) kidney stones; 
or (vii) sarcoidosis; (c) intake of vitamin D supplements containing 
more than 2,000 IU/day of vitamin D3; (d) multiple gestational preg-
nancy; (e) pregnancy achieved by assisted reproductive techniques 
(e.g., IUI, IVF); (f) current use of illicit drugs (defined as any use in 
the past 6 months prior to enrollment); (g) previous enrollment in the 
VDAART for a prior pregnancy; (h) any major fetal anomalies detected 
prior to delivery; (i) patient health questionnaire (PHQ-9) depression 
scale of 15 or higher; (j) any condition, in the opinion of the clinical 
Figure 4. Functional annotation, 
tissue specificity, and PPI network 
mapping of vitamin D signatures 
associated with preeclampsia 
obtained from the gene expression 
study. GO functional enrichment 
analysis was based on a hypergeo-
metric test with an FDR adjustment 
for multiple testing of the identified 
pathways.
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Figure 5. LCC genes (143 genes, highlighted in red) 
corresponding to the “observable preeclampsia mod-
ule” among the replicated differentially expressed 
genes (N = 348) and their biological processes. The 
connectivity of the replicated signatures was explored 
by mapping onto functional protein-protein interaction 
networks from HumanNet v.1.
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an adverse event. Pregnant women with known chronic hypertension 
were excluded from entry into the VDAART. Every month, study coor-
dinators performed a medical record review for cases of preeclampsia 
as part of the protocol for identifying SVEs in the trial. Medical records 
were abstracted for all participants after delivery. A committee of 
4 board-certified obstetricians conducted a blinded review of  276 
abstracted charts of subjects with a noted diagnosis of hypertension, 
proteinuria, or preeclampsia to determine preeclampsia status. The 
diagnosis of preeclampsia at the time of the record reviews was based 
on the American Congress of Obstetricians and Gynecologists (ACOG) 
cations; these were logged, and a severe adverse event (SVE) form or 
an adverse event form was completed as applicable. At 32 to 38 weeks 
of gestation, in addition to the monthly routine, a blood draw, skin 
pigmentation determination, and several of the questionnaires that 
were administered at the enrollment visit were repeated. At delivery, 
cord blood was collected, and the research staff collected informa-
tion regarding the type of delivery, birth weight of the baby, and other 
anthropometric measures from the delivery records.
Study outcome and main predictor measurements. The occurrence 
of preeclampsia was a prespecified secondary outcome of the trial and 
Figure 6. Connection among the vitamin D– and IL-10–signaling pathway genes (blue and yellow modules, respectively) within the module. Only the 
direct connections between vitamin D and IL-10 pathway genes within the module are shown. The size of the circles corresponds to the degree of genes 
in the interactome. The closeness of the vitamin D– and IL-10–signaling pathways to the LCC is based on the observed shortest path between each set of 
genes and the LCC.
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ed cRNA was prepared according to the manufacturer’s protocol, 
and hybridization was processed according to the protocol for the 




After image production and processing, an expression set with 
33,297 probes and 157 samples, collected at 10 to 18 weeks of ges-
tation (enrollment), were generated, representing the 47 subjects 
with preeclampsia and the 110 unaffected normal pregnant wom-
en. In order to check the quality of the arrays, quantiles of expres-
sions were examined before and after normalization. Background 
adjustment, log2 transformation, and quantile normalization were 
performed using the robust multiarray analysis (“rma”) function in 
R BioConductor’s “affy” library to minimize nonbiological variabili-
ty among arrays. Principal component (PC) analysis of samples was 
done to identify any extreme outlier. Thereafter, phenotypes of inter-
est were merged with the expression set. Probes were annotated using 
the annotation package for Bioconductor pd.hugene.1.0.st.v1 and 
confined to annotated probes of autosomal chromosomes (19,137 
probes). The interquartile range (IQR) filter (values of IQR includ-
ing 80% of the probe expressions) was implemented in R using the 
“genefilter” package from Bioconductor to remove expressions 
showing little changes within arrays (47). This process resulted in 
an expression set of 15,309 probes belonging to 157 samples collect-
ed at 10 to 18 weeks of pregnancy, representing 47 preeclampsia cases 
and 110 women. To capture the expression heterogeneity, surrogate 
variable analysis was conducted by applying the surrogate variable 
analysis (SVA) function to the expression data. Accordingly, 16 surro-
gate variables (SVs) were identified and expression data adjusted for 
12 batches uncorrelated to the main predictor of interest, i.e., vitamin 
D serum levels in early pregnancy. Thereafter, differential expression 
analysis was carried out using the Bioconductor package “RankProd,” 
which implements the rank product method for identifying differen-
tially expressed genes (48).
The data discussed in this article were deposited in the NCBI’s 
Gene Expression Omnibus (GEO) database (GEO GSE85307; 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=epajoakqp-
pkvbub&acc=GSE85307).
Microarray validation by quantitative reverse transcription PCR. 
To ensure internal validity, the top ranked up- or downregulated 
genes by RankProd from the replication results were chosen for val-
idation by quantitative reverse transcription PCR (qRT-PCR), and 
qRT-PCR was performed.
Replication cohort. A population selected to replicate the gene 
expression results in the VDAART was obtained from a nested 
case-control study of preeclampsia (Ncases= 16 and Ncontrols= 16) with-
guidelines (43), which included the identification of high blood pres-
sure (BP) and either proteinuria (≥300 mg per 24-hour collection or 
≥1+ on a urine dipstick) or the presence of elevated liver enzymes, high 
platelet count, headache, or visual disturbances after 20 weeks of ges-
tation. High BP was diagnosed for participants who had a systolic BP 
of 140 mmHg or higher, a diastolic BP of 90 mmHg or higher, or both, 
with a second elevated measurement noted in the medical record at 
least 6 hours after the first measurement was taken. Consequently, 
preeclampsia was diagnosed in 67 participants. Total 25OHD levels 
were measured using a chemiluminescence assay on a DiaSorin LIAI-
SON machine at the data coordination center (DCC). We performed 
the 25OHD TOTAL assay, which has shown an excellent correlation 
with the DiaSorin 25OHD RIA assay, which has been used to defined 
reference levels. This method has also exhibited better concordance 
with liquid chromatography–tandem mass spectrometry (LC-MS/MS) 
results as compared with other available methods (44). Additionally, 
using specific polyclonal antibodies, this method avoids the previously 
observed racial differences in vitamin D–binding protein (VDBP) con-
centrations that are most likely due to monoclonal assay bias (45, 46). 
For quality control, our laboratory used the US National Institute of 
Standards and Technology (NIST) level 1 protocol.
Gene expression substudy. Participants of the preeclampsia microar-
ray study comprised a nested case-control group (N = 157) selected 
from among participants of the VDAART. Of the 67 women with pre-
eclampsia, 47 (70.14%) had a suitable RNA sample available at entry 
into the trial (10–18 weeks of gestation) and participated in the gene 
expression substudy. Controls were chosen from the VDAART sub-
jects matched for age (within 5 years), race, and study center, such that 
each subject had 2 matched controls. Once the initial set of matched 
study subjects and controls was formed, additional controls were 
incorporated to enhance the range of 25OHD concentrations present 
among the control subjects (total Ncontrols= 110). In a post-matching 
comparison, we found no significant difference (all P values >0.05) in 
age, race, or maternal gestational age in early pregnancy among the 47 
preeclampsia subjects and the 110 normal controls.
RNA isolation and microarray processing. Total RNA was iso-
lated from whole blood using the QIAGEN PAXgene Blood RNA 
Kit according to the manufacturer’s protocol. The GLOBIN-
clear Kit (Ambion) was used to remove α and β globin mRNA 
from the sample to increase the sensitivity of the gene expres-
sion assays by improving the detection rate of expressed genes. 
The RNA was quantified using the Nanodrop 8000 and checked 
for high integrity before preparation of cDNA. The integrity of RNA 
samples was assessed using the Agilent 2100 Bioanalyzer, and puri-
ty of the samples was confirmed using the NanoDrop spectropho-
tometer and RNA integrity number (RIN ≥8). Gene expression was 
assessed using the Affymetrix Human Gene 1.0 ST Array. Biotinylat-
Table 4. Average distances between the preeclampsia module and vitamin D receptor (VDR) and IL-10 pathways
Pathway closeness to PE module Average distance Random distance SD Z score
IL-10 pathway vs. preeclampsia module 2.45 2.80 0.04 –8.60
VDR pathway vs. preeclampsia module 2.53 2.70 0.045 –3.80
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was less than 0.05. The number of permutations used was set as the 
package default value. We separately identified genes associated with 
high/low vitamin D status (at a cutoff of 30 ng/ml) and preeclampsia 
case status and then identified the overlap of these 2 gene modules. 
We replicated the overlap in our second case-control study using the 
rank product method. Those genes having a P value of less than 0.05 
in the replication population were considered for further investigation 
in the network and pathway analysis as well as for literature curation 
for their relationship to preeclampsia.
In addition to the GeneCards (53) and MetaCore databases 
(https://lsresearch.thomsonreuters.com/pages/solutions/1/metacore) 
(overall 673 annotations), the replicated gene signatures were manual-
ly curated in order to validate their connection to preeclampsia accord-
ing to the scientific literature and previous preeclampsia research. 
Using the Human Protein Atlas (HPA), the subset of replicated signa-
tures with evidence of tissue-specific expression in placenta was iden-
tified (54). Figures 3 and 4 provide an overview of our approach and a 
summary of the results.
Molecular and functional interaction gene networks. The connectivi-
ty of the replicated signatures was explored by mapping onto function-
al protein-protein interaction networks from HumanNet v.1 (55). The 
identified gene set (preeclampsia module) was subsequently used to 
construct the “observable preeclampsia module,” defined as the larg-
est connected component (LCC) of the replicated signature genes (17). 
Thereafter, the connectivity of this module to the known vitamin D– 
and IL-10–signaling pathways using available data from the National 
Cancer Institute’s (NCI’s) Pathway Interaction Database (http://pid.
nci.nih.gov) was explored. GO enrichment analysis was conducted to 
investigate the biological processes involved in the identified modules 
(56). Further details on the methods are provided in Figure 2.
Molecular interaction networks and pathway enrichment analysis. 
To understand the functional relationships underlying the set of rep-
licated differentially expressed genes, we explored their connectivity 
in the HumanNet functional network (55). HumanNet uses a naive 
Bayes approach to weight different types of evidence together into 
a single interaction score focusing on data collected from humans, 
yeast, worms, and flies. We mapped the differentially expressed 
genes encoding proteins in the interactome and identified the LCC 
(or “observable preeclampsia module,” Figure 5) (17). Furthermore, 
we tested the closeness of the observable preeclampsia module to the 
vitamin D and IL-10 pathways, as described below. Ordered function-
al enrichment for the representative GO terms “biological processed,” 
“molecular function,” and “cell component” annotations for both the 
replicated gene set and observable preeclampsia module was carried 
out with g:Profiler (56, 57). Accordingly, gene group functioning pro-
filing was performed with default options limiting the output to signif-
icant results (multiple testing–corrected P < 0.05).
Connectivity of preeclampsia module to vitamin D receptor and IL-10 
pathways. We defined vitamin D and IL-10 pathways as reported in 
the NCI’s Pathway Interaction and BioCarta databases, respectively 
(http://pid.nci.nih.gov). To test whether the observable preeclampsia 
module was connected to vitamin D and IL-10 pathways, we mea-
sured the closeness between the 2 sets of genes and compared this 
parameter with that having a random expectation of closeness (Figure 
6). The assumption behind this exercise was that, even if the genes 
did not overlap between the preeclampsia module and vitamin D and 
IL-10 pathways, they should be localized in the same neighborhood 
in the OMEGA study, a prospective cohort study designed to assess 
dietary and other lifestyle risk factors of preeclampsia and other med-
ical complications of pregnancy (49). Participants were nulliparous 
women, who initiated prenatal care at the Swedish Medical Center in 
Seattle, Washington, USA. Transcriptional data for 2 cases were of low 
quality and therefore omitted from the analysis.
Quality control of the replication data. Gene expression of subjects 
was profiled using Affymetrix GeneChip Arrays. Quantiles of raw 
expression and principal compontents (PCs) across arrays were exam-
ined before and after background adjustment normalization and log2 
using the “rma” function in the R “affy” library. Expression data for 
2 of the samples were identified as outliers and removed, and quan-
tile-normalized and background-adjusted expression data as well as 
PCs were reexamined. The results were compared by running the 
“QCReport” function in the R library’s “affyQCReport.” The microar-
ray expression data were annotated using “hgu133plus2,” available 
on Bioconductor. The annotated expression from autosomal chro-
mosomes was included in the analysis. The final expression data set 
contained 40,003 rows of background-adjusted, log2-transformed, 
rma-summarized, and quantile-normalized expression data for 14 
preeclampsia cases and 16 controls.
Statistics. In accordance with the ITT paradigm, data for all wom-
en (N = 816) were analyzed according to the group to which they were 
randomly assigned (Figure 1). For demographic data, continuous vari-
ables were compared using the appropriate 2-tailed t test or χ2 test, and 
a P value of less than 0.05 was considered statistically significant.
A vitamin D level of 30 ng/ml (75 nmol/l) was used to differenti-
ate between high and low levels (high-high, high-low or low-high, and 
low-low) at both study time points. Selection of this cutoff was mostly 
based on the observations of several studies designed to investigate the 
relationship between serum parathyroid hormone (PTH) and 25OHD 
levels in adults. These studies have shown that the suppression of PTH 
reaches a plateau when the 25OHD level approximates 30 ng/ml (50). 
Of note, it has been demonstrated that during pregnancy, serum PTH 
levels are not different from those of nonpregnant women (51, 52).
Two ITT analyses were performed: (a) For the primary outcome 
assessment, we used logistic regression analysis, controlling for a 
priori covariates or potential confounders (associated with primary 
outcome and the main variable of vitamin D status at a significance 
level of 0.2; Table 2 and Supplemental Table 6) including gravidity, 
age, race, BMI, study group designation, education level, income, and 
study center; (b) within-group and group-collapsed trend tests of cat-
egorical 25OHD concentration effects on preeclampsia development 
were applied. Finally, we evaluated the dose-response association 
between maternal vitamin D serum concentrations at 10 to 18 weeks 
of gestation and risk of preeclampsia after adjustment for the informa-
tive variables identified in the primary outcome analysis (Table 2). For 
all of the ITT analyses, 2-sided P values of less than 0.05 were consid-
ered statistically significant.
Transcriptomic variations related to preeclampsia. SV analyses 
were conducted, and tests for differential gene expression included 
an adjustment for expression heterogeneity. Differential expression 
analysis was carried out using the Bioconductor “RankProd” package, 
which implements the rank product method for identifying differen-
tially expressed genes (48). Differentially expressed (up- or downreg-
ulated) genes were identified through permutation analysis, after set-
ting the percentage of the false prediction threshold for which the FDR 
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of the interactome. The closeness was computed as the average of all 
possible shortest paths between 2 sets of genes, according to the fol-
lowing formula: 
    (Equation 1)
In this formula, d(s, t) is the shortest path from a gene s in the pre-
eclampsia module (Pm), and a gene t of the interest pathway (Pw), and 
NPm and NPw denote the number of genes in each set. To determine the 
significance of this quantity, we selected NPm genes at random in the 
network and determined the average distance (Avg distrand) to the Pm. 
This exercise was repeated 1,000 times, and the significance was eval-
uated by computing the Z score as follows:
    (Equation 2)
In this formula, μ(Avg distrand) and ϭ(Avg distrand) denote the mean 
value and SD of the random expectation. Any distance with a Z score 
lower than –1.65 (i.e., modules closer than expected) was deemed sig-
nificant; as such, a cutoff corresponded to P ≈ 0.05 in the case of a nor-
mally distributed variable.
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